Press Releases

Liquidia Corporation Announces Updates to Operations Leadership

MORRISVILLE, N.C. , Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder.
Jan 19, 2024

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C. , Jan. 05, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company)
Jan 05, 2024

Liquidia Corporation Announces $100 Million in New Financings

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement Additional advance of $25.0 million from HealthCare Royalty under current financing agreement MORRISVILLE, N.C. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA)
Jan 04, 2024

Liquidia Announces Pricing of Public Offering of Common Stock

MORRISVILLE, N.C. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million , before
Dec 12, 2023
Displaying 11 - 20 of 177